1569986-91-9

Upstream product

• 446-38-8 2-fluoro-4-methoxy-1-nitro-benzene 
• 458-52-6 2-fluoro-4-(methoxy)aniline 

Downstream Products

• 1407520-21-1 C₁₂H₁₈N₄O₃ 
• 1407520-27-7 2-(2-(dimethylamino)ethoxy)-4-methoxy-5-nitroaniline 

Relevant academic research and scientific papers

TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The invention discloses a triazine derivative and a pharmaceutically acceptable salt, a pharmaceutical composition and use thereof. Particularly, the invention discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are defined as described in the description and claims. The compound or a salt thereof according to the invention may be used for treating or preventing diseases or conditions by regulating some mutation forms of epidermal growth factor receptors. The invention also discloses a pharmaceutical composition comprising the compound or a salt thereof, and a method for treating various forms of EGFR-mediated diseases (including non-small cell lung cancer) by using the compound and a salt thereof.

Boron-containing compound used as tyrosine kinase inhibitor

The application belongs to the field of medicine and particularly relates to a boron-containing compound used as a tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical compositioncontaining the compound, and a use of the boron-containing compound in treatment on tyrosine kinase-mediated cell proliferative diseases. The boron-containing compound can well inhibit tyrosine kinase.

PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative,and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS

Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.